ESPE Abstracts

Background: The efficacy and safety of rhGH treatment on ISS and GHD were not reported in Chinese children. In this study, we aimed to compare the efficacy and safety of rhGH therapy in ISS and GHD.

Methods: The clinical data in children with ISS and GHD who were treated with rhGH for more than one year from 2005 to 2016 were retrospectively analyzed. Growth velocity (GV), HtSDS, IGF1 SDS, BMI and the incidence of fasting hyperglycemia, fasting hyperinsulinmia and hypothyroidism were recorded and compared.

Results: 150 ISS and 153 GHD children who received rhGH treatment more than one year were enrolled. Two groups had no significant differences in the age of treatment, bone age, height and BMI. GV in GHD was higher than ISS group but there was no significant difference in GV between the two groups (P>0.05). HtSDS at the beginning of treatment and half year of treatment were significantly lower than the ISS group (P<0.05). The incidence of hypothyroidism in GHD group was significantly higher than that in ISS group (13.72% vs 6.0%, P<0.05). The incidence of hyperinsulinmia in ISS group was significantly higher than that in ISS group (15.33% vs 7.84%, P<0.05).

Conclusion: rhGH has a similar effect on the growth of ISS and GHD. Children with ISS are more likely to develop fasting hyperinsulinmia, and children with GHD are more likely to have hypothyroidism.